Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany - PubMed

3 days ago

Molecular Tumor Boards (MTBs) aim to identify targetable molecular alterations for individualized treatment in advanced melanoma, but real-world data on their impact is limited.
In a bicenter retrospective analysis of 80 advanced melanoma patients, most (88.3%) had stage IV disease and had received a median of three prior systemic treatments.
Actionable treatment recommendations were made in 77.9% of eligible cases, but only 33.7% were implemented, with non-implementation often due to early patient death or regulatory barriers.
When MTB-recommended therapies were applied, patients showed significantly improved progression-free survival (7.85 vs. 4.34 months) and overall survival (10.64 vs. 5.06 months) compared to those without implementation.
Among patients with implemented recommendations, 53.8% achieved a progression-free survival ratio ≥ 1.3, indicating meaningful clinical benefit from molecularly guided treatments.
The study highlights that late-stage referral limits MTB implementation and underscores the need for earlier integration of MTBs into melanoma care pathways.

Hasty Briefsbeta